BCAX Form 144: Insider Sale of 10,900 Shares Worth $196.2K

Bicara Therapeutics (BCAX) filed a Form 144 disclosing a proposed sale of 10,900 common shares through UBS Financial Services on 10/07/2025 with an aggregate market value of $196,200.

Accepted by SEC EDGAR 10/07/2025 - 04:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Bicara Therapeutics (BCAX) filed a Form 144 disclosing a proposed sale of 10,900 common shares through UBS Financial Services on 10/07/2025 with an aggregate market value of $196,200. The filing lists total outstanding shares of 54,562,841, indicating the sale represents a very small fraction of the company.

The securities were acquired in two non‑qualified option-related transactions: 2,900 shares on 05/12/2024 and 8,000 shares on 10/06/2025, both paid in cash to the issuer. The filer also reported prior sales of 39,600 shares on 10/06/2025 producing gross proceeds of $714,997.10. By signing, the seller represents they have no undisclosed material information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BCAX Form 144 disclose?

The Form 144 discloses a proposed sale of 10,900 common shares via UBS on 10/07/2025, with an aggregate market value of $196,200.

How many shares did the filer acquire and when?

The filer acquired 2,900 shares on 05/12/2024 and 8,000 shares on 10/06/2025, both noted as NQ exercise/NQSO transactions paid in cash.

Has the filer sold any BCAX shares recently?

Yes. The filing shows prior sales of 39,600 shares on 10/06/2025 for gross proceeds of $714,997.10.

What broker is handling the sale and where will the shares trade?

UBS Financial Services, Inc. is listed as the broker and the securities are named for sale on Nasdaq.

Does the filer attest to disclosure status?

Yes. By signing the notice the filer represents they do not know any material nonpublic information about the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034665
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Cohlhepp Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	President and COO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	10900	196200.00	54562841	10/07/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/12/2024	NQ Exercise shares	Issuer			2900	05/12/2024	Cash
Common	10/06/2025	NQSO	Issuer			8000	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ryan Cohlhepp 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	10/06/2025	39600	714997.10

144: Remarks and Signature

Remarks
Date of Notice	10/07/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ryan Cohlhepp
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)